相关实验视频

Updated: Jan 15, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

酒精消费,过度营养和肝硬化药物治疗之间的相互关系:考虑和建议

Rodrigo Valenzuela¹, Camila Farías¹, Yasna Muñoz²

¹Nutrition Department, Faculty of Medicine, University of Chile, Santiago, 8380453, Chile.

Molecular and cellular endocrinology

|October 11, 2025

概括

酒和过度营养会独立引起肝硬化,但它们的联合作用会显著恶化病情. 需要进一步的研究来开发脂肪肝疾病的有效治疗策略.

科学领域:

肝病学肝病学是一种肝病学.
代谢障碍代谢障碍代谢障碍
毒理学毒理学毒理学

背景情况:

肝脂肪症,或脂肪肝疾病,与滥用酒精和过度营养有关.
酒精代谢通过酒精脱酶 (ADH) 和细胞染色体P450 2E1 (CYP2E1) 增加NADH/NAD+比率和氧化应激,产生有毒的乙甲.
过度营养涉及高能量摄入量,精制碳水化合物,和脂肪,以及低纤维/水果/蔬菜/n-3 PUFA摄入量,破坏脂质代谢.

研究的目的:

探索导致酒精和过度营养的肝硬化症的机制.
为了研究酒精和营养过度暴露在肝脏肥胖症上的协同效应.
审查当前和潜在的治疗策略来管理肝硬化症.

主要方法:

关于酒精和过度营养的联合影响的临床前研究的审查.
分析受酒精氧化和过度营养影响的代谢途径.
对已探索的抗肥胖药物和组合疗法的调查.

主要成果:

酒精和过度营养都会通过改变的NADH/NAD+比率和脂质生成独立诱导肝肥胖症.
临床前数据表明,与单个暴露相比,联合暴露显著加剧了肝硬化症.
现有的治疗干预表明不一致的结果,突出需要更好的指导策略.

结论:

了解酒精和过度营养的协同影响对于有效的肝硬化症管理至关重要.
对综合风险因素的进一步研究对于开发标准化治疗方案至关重要.
迫切需要指导卫生专业人员预防和逆转肝硬化症的策略.

关键词:

酒精消费酒精消费酒精消费肝脏肥胖症肝脏肥胖症马夫尔德 (MAFLD) 是一个过度营养过度营养氧化应激是一种氧化应激.药物治疗药物治疗

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...